medigraphic.com
ISSN 1684-1824 (Electronic)

2014, Number 5

<< Back Next >>

Rev Méd Electrón 2014; 36 (5)

Brain pseudo tumor in the course of a primary anti phospholipidic syndrome. Case presentation

García GA, Ruiz HI, Salgado ML, Guerra AM, López GY

Language: Spanish
References: 10
Page: 665-670
PDF size: 202.84 Kb.


ABSTRACT

The anti phospholipidic syndrome as cause of a multiple endothelial dysfunction is usually associated to many autoimmune diseases and, occasionally, precedes them many years. We present the case of a female patient, aged 36 years with healthy antecedents, who entered the hospital with convulsions associated to a right hemiparesis with central facial taking and left frontal parietal tomographic images that are compatible with a possible metastatic brain tumor. Looking for the primary lesion, several hematologic, ultrasonographic and radiologic studies were carried out, showing negative results. During her hospital staying, she had a left pleural effusion and a deep venous thrombosis in both lower limbs. After a 45-days staying in the hospital, and due to her recovery and all-symptoms regression, an evolution magnetic resonance was carried out, showing the total disappearance of the neurologic lesion; we arrived to the conclusion that it was a brain pseudo tumor in the course of a primary anti phospholipidic syndrome.


REFERENCES

  1. Pouymiró Pubillones PO, Pouymiró Brooks Y, Pouymiró Brooks I. Síndrome de anticuerpos antifosfolípidos. Medisan [Internet]. 2012 [citado 20 Ago 2013];16(3). Disponible en: http://bvs.sld.cu/revistas/san/vol_16_3_12/san14312.htm

  2. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237-42. Citado en PubMed; PMID: 19874470.

  3. Alarcon-Segovia D, Sánchez-Guerrero J. Síndrome antifosfolipídico primario R. Reumatología. 1989; 16:482-9.

  4. Farreras R. Medicina Interna. 13a ed. T. 3. La Habana: Editorial Ciencias Médicas; 2011.

  5. Harrison TL. Manual de Medicina. 16a ed. Madrid: Ed. Mc Graw- Hill; Parte XIII. 2006.

  6. Devreese K, Hoylaetrs MF. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem. 2010;56(6):930-40. Citado en PubMed; PMID: 20360130.

  7. Agar C, Van Os GM, Mörgelin M, Sprenger RR, Marquart JA, Urbanus RT, et al. Beta2- â2-Glycoprotein I can exist in two conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116(8):1336-43. Citado en PubMed; PMID: 20462962.

  8. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ. 2010; 340:2541. Citado en PubMed; PMID: 20472677.

  9. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330-9. Citado en PubMed; PMID: 21556027.

  10. Castillo González DC, Almagro Vázquez D, Díaz Concepción A. Anticoagulante lúpico en enfermedades autoinmunes. Instituto de Hematología e Inmunología. Habana. Rev Cubana Hematología [Internet]. 2004 [citado 20 Ago 2013];20(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892004000200007




2020     |     www.medigraphic.com